/4523.T

4523.T Stock - Eisai Co., Ltd.

Q: What is the analyst price target for 4523.T?

Analyst price target information is not currently available for 4523.T.

Q: What is 4523.T's market cap?

Market capitalization information is not currently available for 4523.T.

Healthcare|Drug Manufacturers - Specialty & Generic|JPX

$4608.00+1.16%

+$53.00 (+1.16%) • Dec 24

GoAI Score

Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.

HOLD

Medium Confidence

Momentum

Momentum Score

Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.

Sentiment

Sentiment Score

Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).

Risk Score

Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.

100

Price Target

Average analyst price target from the last quarter. Shows expected upside/downside from current price.

+10.0%upside

Target: $5068.80

AI Analysis PreviewPremium

Real-time AI-powered market analysis

Precise entry/exit price targets

Risk assessment & position sizing

Unlock GoAI Insights for 4523.T

Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.

Buy/Sell Signals

94% win rate on Alpha signals

Deep Analysis

Institutional-grade thesis

Real-Time Alerts

SMS & push notifications

Risk Scoring

Multi-factor analysis

Free 14-day trial • No credit card required

Financial Statements

Revenue & Profitability Trend

FY2020

FY2021

FY2022

FY2023

FY2024

← Swipe to see more →

Revenue

Net Income (Profit)

Net Loss

Key Metrics

Market CapN/A

P/E RatioN/A

Beta-0.27

52W High$5349.00

52W Low$3463.00

Avg VolumeN/A

Income Statement (Fiscal Year)

Metric	FY2024	FY2023	FY2022	FY2021	FY2020
Revenue	$789.40B	$741.75B	$744.40B	$756.23B	$645.94B
Gross Profit	$620.59B	$586.42B	$566.57B	$581.39B	$484.63B
Gross Margin	78.6%	79.1%	76.1%	76.9%	75.0%
Operating Income	$40.98B	$53.41B	$35.27B	$53.75B	$56.54B
Net Income	$46.43B	$42.41B	$55.43B	$47.95B	$41.94B
Net Margin	5.9%	5.7%	7.4%	6.3%	6.5%
EPS	$163.76	$147.86	$193.31	$167.27	$146.95

Company Overview

Eisai Co., Ltd. offers pharmaceutical products in Japan. It offers Aricept for the treatment of alzheimer's disease/dementia with Lewy bodies; Methycobal for the treatment of peripheral neuropathy; and Fycompa, an antiepileptic drug for the adjunctive treatment of partial-onset and primary generalized tonic-clonic seizures. The company also provides Lyrica for pain treatment; Dayvigo, an anti-insomnia drug for the treatment of adults with insomnia; Lenvima, an anticancer agent/molecular targeted medicine for the treatment of thyroid cancer, renal cell carcinoma in combination with everolimus, and hepatocellular carcinoma; and Halaven, an anticancer agent/microtubule dynamics inhibitor for the treatment of breast cancer and liposarcoma. In addition, it offers Pariet, a proton-pump inhibitor for the treatment of gastric and duodenal ulcers, reflux esophagitis, and eradication of Helicobacter pylori infections, etc.; Humira, a fully human anti-TNF-a monoclonal antibody for the treatment of autoimmune diseases, such as rheumatoid arthritis; and Chocola BB plus, a vitamin B2 preparation for rough skin and stomatitis, as well as various products, which include third-class OTC drugs, designated quasi-drugs, and food with nutrient function. The company was formerly known as Nihon Eisai Co., Ltd. and changed its name to Eisai Co., Ltd. in 1955. Eisai Co., Ltd. was incorporated in 1941 and is headquartered in Tokyo, Japan.

Visit Website

Earnings History & Surprises

4523.T

Beat Rate

61%

Last 18 quarters

Avg Surprise

+23.4%

EPS vs Estimate

Beats / Misses

11/7

Last 12 quarters

Latest EPS

$36.02

Q4 2025

EPS Surprise History

Q2 24

+12.9%

$46.40vs$41.10

Q3 24

+51.1%

$36.95vs$24.46

Q4 24

+37.9%

$39.18vs$28.42

Q1 25

+102.1%

$84.31vs$41.71

Q2 25

-80.3%

$3.51vs$17.81

Q3 25

+32.5%

$51.35vs$38.76

Q3 25

+32.5%

$51.35vs$38.76

Q4 25

-26.2%

$36.02vs$48.82

Beat Estimate

Missed Estimate

Quarterly EPS Details

Period	Report Date	Estimated EPS	Actual EPS	Surprise	Result
Q2 2026	May 13, 2026	—	—	—	—
Q1 2026	Feb 5, 2026	—	—	—	—
Q4 2025	Nov 5, 2025	$48.82	$36.02	-26.2%	✗ MISS
Q3 2025	Aug 5, 2025	$38.76	$51.35	+32.5%	✓ BEAT
Q3 2025	Aug 5, 2025	$38.76	$51.35	+32.5%	✓ BEAT
Q2 2025	May 13, 2025	$17.81	$3.51	-80.3%	✗ MISS
Q1 2025	Feb 4, 2025	$41.71	$84.31	+102.1%	✓ BEAT
Q4 2024	Nov 8, 2024	$28.42	$39.18	+37.9%	✓ BEAT
Q3 2024	Aug 2, 2024	$24.46	$36.95	+51.1%	✓ BEAT
Q2 2024	May 15, 2024	$41.10	$46.40	+12.9%	✓ BEAT
Q1 2024	Feb 6, 2024	$27.33	$20.82	-23.8%	✗ MISS
Q4 2023	Nov 7, 2023	$26.59	$9.72	-63.4%	✗ MISS
Q3 2023	Aug 2, 2023	$20.95	$70.92	+238.5%	✓ BEAT
Q2 2023	May 15, 2023	$80.46	$56.92	-29.3%	✗ MISS
Q1 2023	Feb 6, 2023	$29.76	$30.14	+1.3%	✓ BEAT
Q4 2022	Nov 7, 2022	$27.11	$12.44	-54.1%	✗ MISS
Q3 2022	Aug 5, 2022	$35.19	$93.81	+166.6%	✓ BEAT
Q2 2022	May 13, 2022	$-15.47	$-43.27	-179.7%	✗ MISS
Q1 2022	Feb 3, 2022	$47.05	$49.43	+5.1%	✓ BEAT
Q4 2021	Nov 1, 2021	$4.72	$14.04	+197.5%	✓ BEAT

Frequently Asked Questions about 4523.T

What is 4523.T's current stock price?

Eisai Co., Ltd. (4523.T) is currently trading at $4608.00 per share. The stock has moved +1.16% today.

What is the analyst price target for 4523.T?

No analyst price targets are currently available for this stock.

What sector is Eisai Co., Ltd. in?

Eisai Co., Ltd. operates in the Healthcare sector, specifically within the Drug Manufacturers - Specialty & Generic industry. The company is traded on the JPX exchange.

What is 4523.T's market cap?

Eisai Co., Ltd. has a market capitalization of $1299.98 billion, making it a mega-cap company.

Does 4523.T pay dividends?

No, Eisai Co., Ltd. does not currently pay a dividend to shareholders.